BOSTON & MONTREAL, June 25, 2025--enGene Holdings Inc. (Nasdaq: ENGN, or "enGene" or the "Company"), a clinical-stage, ...

In an interview with Targeted OncologyTM, Ravi Muvner, MD, urologist at Hackensack University Medical Center, discusses how targeted therapies have changed the landscape of prostate cancer treatment.

CG Oncology, Inc.'s promising bladder cancer therapy, strong financials, and unique therapeutic profile make it a compelling ...

The Food and Drug Administration (FDA) has approved Zusduri (mitomycin intravesical solution) for adults with recurrent low-grade intermediate-risk non-muscle invasive bladder cancer (NMIBC).

Additionally, multivariable analyses demonstrated that detectable ctDNA before radical cystectomy was associated with a higher risk of nodal disease (OR 5.4, 95% CI 1.9-18.2; p = 0.003) and locally ...

In the neoadjuvant and adjuvant phases of arm C, pembrolizumab will be administered on day 1 and enfortumab vedotin will be administered on days 1 and 8 of each cycle. Enrollment is complete for arm A ...

Ferring Pharmaceutical officially opened its new 12,000-square-foot gene therapy manufacturing facility located within its US ...

A Bridgeport resident says the CT DOC's failure to provide timely treatment led to 28 rounds of chemotherapy and the removal ...

EAU guidelines offer updated guidance on diagnosis, treatment, & follow-up of patients with metastatic & muscle-invasive ...

ENGN maintains a cash runway into 2027, supporting ongoing development without major liquidity concerns in near term. Click ...

A breakthrough in bladder cancer treatment at the University of California, Davis: multifunctional nanoparticles enhance ...

Scientists at UC San Francisco have found a way to identify and possibly treat a mysterious type of bladder cancer that affects up to 1 in 4 cases.